High quality DNA and RNA are important for a wide variety of research and clinical applications. Purification or isolation of nucleic acids is the first step in most molecular biological studies and in all recombinant DNA techniques. The extraction of nucleic acids from biological material requires cell lysis, inactivation of cellular nucleases, and separation of the desired nucleic acid from cellular debris. Methods for purifying nucleic acids from cell extracts are often combinations of extraction/precipitation, chromatography, centrifugation, electrophoresis, and affinity separation. Pure nucleic acid has applications in emerging fields such as genetic engineering, molecular diagnosis, forensics, and research related to life sciences.
Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2420
Increasing demand for nucleic acid test that is required for pipeline studies of genetic engineering and molecular diagnostics is the key driver for nucleic acid isolation and purification market growth. For Instance, in September 2012, GlaxoSmithKline initiated Phase 1 clinical study to evaluate the effects of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable, metastatic or recurrent synovial sarcoma. T immune cells are genetically engineered to express tumor-specific T cell receptor (TCR) genes and thereby kill cancer cells. The study is expected to complete by May 2020.
However, low adoption of automated nucleic acid isolation and purification procedures in emerging economies is a key factor restraining the global nucleic acid isolation and purification market growth.
On the basis of region, the global nucleic acid isolation and purification market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Increasing merger and acquisition activities in North America are expected to drive the nucleic acid isolation and purification market size. For Instance, in May 2018, Agilent Technologies Inc. acquired Lasergen, Inc. in a US$ 105 million deal. The collaboration has been done to develop next-generation sequencing workflow solutions for clinical applications.
Furthermore, key players in Europe are focused on adopting acquisition strategies in order to enhance their market share. This in turn is expected to boost growth of the nucleic acid isolation and purification market in the region. For Instance, in February 2017, Qiagen Inc. acquired OmicSoft Corp. OmicSoft is recognized for its suite of software solutions that enable researchers to analyze and visualize their own datasets and compare them to massive volumes of publicly available ‘omics’ datasets. This acquisition aims at adding feature to the management, analysis, and sharing of both primary data and analyzed results, while also expanding the range of Qiagen’s translational and clinical applications.
Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2420
Key players operating in the nucleic acid isolation and purification market include QIAGEN Inc., Thermo Fisher Scientific., F. Hoffmann-La Roche Ltd, Merck KGaA,, Agilent Technologies Inc., Illumina, Inc., Takara Bio Inc., Promega Corporation, General Electric Company, Danaher Corporation, New England Biolabs, and Bio-Rad Laboratories.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.